Compare Amphastar Pharmaceuticals Inc (AMPH) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Trip.com Group Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Trip.com Group Ltd trades at $42.79 (market cap $26.45B). The key difference: Trip.com Group Ltd is far larger — about 32× Amphastar Pharmaceuticals Inc's market cap, and Trip.com Group Ltd pays a 0.57% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TCOM | |
|---|---|---|
Market Cap | $826.08M | $26.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $78.96 |
52-Week Low | $16.87 | $39.84 |
Enterprise Value | $1.22B | $19.15B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Trip.com Group (TCOM) trades at $42.80, up 3.31% on the day, with strong fundamentals including a P/E of 6.43 and net income margin of 48.65%. The stock faces technical headwinds with a bearish signal from moving averages and RSI at 82.74 suggesting overbought conditions. Recent Q1 2026 earnings missed expectations at $0.83 vs. $0.85, while revenue guidance for Q2 2026 of 3%-8% growth disappointed investors, triggering an 18% selloff on June 29, 2026.
Despite near-term pressure from regulatory scrutiny and conservative guidance, Trip.com maintains robust profitability and analyst consensus of $56.72 price target with 67% buy ratings. The company's dominant position in China's travel market and strong cash flow generation provide long-term upside potential, though regulatory risks and margin compression remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
